Selecta Biosciences, Inc.

Astellas Pharma, Inc. has a sharp eye on deal-making opportunities, including for late-stage assets, but a thrust on launch execution for key products and controlling expenses is where much of the ac

In the fourth quarter of 2023, Casgevy (exagamglogene autotemcel) – a CRISPR-based therapeutic developed by Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG – was approved by the US

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lenz/Graphite Combination Is All-Stock

The US Federal Trade Commission’s legal challenge to block Amgen, Inc. ’s proposed acquisition of Horizon Therapeutics plc was resolved with the agency formalizing Amgen’s commitment not to bundle